Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.39 |
| ▸ | OGA | O60502 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12556044 | 0.83 | ESR1 (0.40) | FFAR1ABCB11ESR1ESR2 | |
| SCHEMBL1933116 | 0.81 | ESR1 (0.40) | FFAR1ESR1ESR2 | |
| SCHEMBL6296267 | 0.81 | ESR2 (0.59) | ESR1ESR2 | |
| SCHEMBL13820456 | 0.80 | FFAR1 (0.54) | FFAR1ESR1ESR2 | |
| SCHEMBL6292853 | 0.80 | HTR1A (0.45) | — | |
| SCHEMBL13720329 | 0.75 | LPL (0.35) | FFAR1ESR1ESR2 | |
| SCHEMBL16857321 | 0.75 | SNRNP200 (0.37) | ESR1ESR2 | |
| SCHEMBL6291943 | 0.73 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL11039123 | 0.73 | ESR1 (0.43) | ESR1ESR2 | |
| SCHEMBL10263203 | 0.72 | OGA (0.37) | FFAR1OGAESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289501-A1 | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | CYP1B1, CYP11B2, CCNI | FFAR1 3100/4885ABCB11 611/4885OGA 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.